{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:09:27Z","timestamp":1784041767218,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.jaad.2006.09.013","type":"journal-article","created":{"date-parts":[[2006,12,5]],"date-time":"2006-12-05T07:11:14Z","timestamp":1165302674000},"page":"460-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Nail toxicity associated with epidermal growth\u00a0factor receptor inhibitor therapy"],"prefix":"10.1016","volume":"56","author":[{"given":"Lindy P.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.09.013_bib1","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.013_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jaad.2006.09.013_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2006.09.013_bib4","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.013_bib5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2006.09.013_bib6","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"17","author":"Perez-Soler","year":"2003","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/j.jaad.2006.09.013_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/dot.2005.41.2.882662","article-title":"Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody","volume":"41","author":"Harding","year":"2005","journal-title":"Drugs Today (Barc)"},{"issue":"Suppl","key":"10.1016\/j.jaad.2006.09.013_bib8","first-page":"77","article-title":"Phase III randomized trial of cisplatin + placebo versus cisplatin + C225, a monoclonal antibody directed to the epidermal growth factor receptor: an Eastern cooperative oncology group trial","volume":"9","author":"Burtness","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.013_bib9","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth\u00a0factor\u00a0receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.013_bib10","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.013_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ijgc-00009577-200509000-00012","article-title":"Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study","volume":"15","author":"Gordon","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jaad.2006.09.013_bib12","series-title":"Iressa","year":"2003"},{"key":"10.1016\/j.jaad.2006.09.013_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.09.013_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.013_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the\u00a0antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.09.013_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.09.013_bib17","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Complications of therapy in cancer patients, case 1: paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.013_bib18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","article-title":"Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor","volume":"147","author":"Van Doorn","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.09.013_bib19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2006.09.013_bib20","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: URL:http:\/\/www.ctep.cancer.gov\/reporting\/ctcnew.html. Accessed November 15, 2005."},{"key":"10.1016\/j.jaad.2006.09.013_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.013_bib22","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1200\/JCO.2003.04.169","article-title":"Complications of therapy and a diagnostic dilemma case, case 2: cutaneous toxicity induced by cetuximab","volume":"21","author":"Monti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.013_bib23","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1046\/j.1365-2133.1999.02883.x","article-title":"Paronychia associated with antiretroviral therapy","volume":"140","author":"Tosti","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.09.013_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2230.1986.tb00439.x","article-title":"Etretinate and the nails (study of 130 cases) possible mechanisms of some side effects","volume":"11","author":"Baran","year":"1986","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.09.013_bib25","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/emboj\/cdf331","article-title":"Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled","volume":"21","author":"Chapellier","year":"2002","journal-title":"EMBO\u00a0J"},{"key":"10.1016\/j.jaad.2006.09.013_bib26","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1096\/fasebj.10.9.8801161","article-title":"Molecular mechanisms of retinoid actions in skin","volume":"10","author":"Fisher","year":"1996","journal-title":"FASEB J"},{"key":"10.1016\/j.jaad.2006.09.013_bib27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000073100","article-title":"Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor","volume":"207","author":"Dainichi","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.09.013_bib28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"47","author":"Boucher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.09.013_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1346-8138.2003.tb00387.x","article-title":"Paronchia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor","volume":"30","author":"Nakano","year":"2003","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2006.09.013_bib30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","article-title":"Doxycyclene for\u00a0the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab","volume":"154","author":"Suh","year":"2006","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206025394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206025394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:06:12Z","timestamp":1759269972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206025394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0190962206025394"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.09.013","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nail toxicity associated with epidermal growth\u00a0factor receptor inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}